| Serial measurements of high sensitive cardiac troponin I in patients with acutely decompensated heart failure treated with carperitide or nitrates. | |
| | |
MedLine Citation:
|
PMID: 20381318 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: In patients with acutely decompensated heart failure (ADHF), elevated serum concentration of cardiac troponin is an independent predictor of adverse cardiac events. In ADHF with a preserved systolic blood pressure, treatment with intravenous vasodilator is recommended. However, the effect of vasodilators on troponin concentrations has not been elucidated well. METHODS AND RESULTS: Serial high sensitive cardiac troponin I (hs-TnI) was measured in 36 patients presenting with ADHF and preserved systolic blood pressure, of whom 20 were treated with atrial natriuretic peptide (ANP) and 16 with nitrates. The concentrations of hs-TnI ranged from 0.069+/-0.114ng/ml at baseline to 0.076+/-0.121ng/ml at 5h, 0.062+/-0.106ng/ml at 1 day, and 0.056+/-0.089ng/ml at day 7 (n=36,ns). The relative change in hs-TnI between baseline and at 5h, day 1 and day 7 were 1.13+/-0.43, 0.95+/-0.44 and 0.93+/-0.64 in patients treated with ANP, and 1.02+/-0.19, 0.95+/-0.31 and 1.19+/-1.38 in patients treated with nitrates (ns; ANP versus nitrates). On day 7, a hs-TnI change, >20% decrease from baseline, was observed in 55% patients with ANP versus 56% patients with nitrates (ns). The cardiac event rates were similar in both groups. CONCLUSIONS: In ADHF patients with preserved systolic blood pressure, the administration of intravenous vasodilators did not decrease hs-TnI over the first 7 days. Treatments with ANP and nitrates were associated with similar short-term decreases in hs-TnI and long-term adverse cardiac events. |
| | |
Authors:
|
Yukihito Sato; Kiyoto Nishi; Sayaka Saijo; Yohei Tanada; Taisuke Goto; Naoki Takahashi; Erika Yamamoto; Rei Fukuhara; Tadashi Miyamoto; Ryoji Taniguchi; Hisayoshi Fujiwara; Yoshiki Takatsu |
Related Documents
:
|
16014188 - Levels of brain natriuretic peptide in children with right ventricular overload due to ... 1972668 - Hemodynamic interactions of atrial natriuretic factor with the sympathetic nervous syst... 14568998 - Chronic administration of adrenomedullin attenuates transition from left ventricular hy... 10233038 - Atrial, b-type, and c-type natriuretic peptides cause mesenteric vasoconstriction in co... 16014188 - Levels of brain natriuretic peptide in children with right ventricular overload due to ... 696878 - Effect of indomethacin on coronary vascular response to increased myocardial oxygen con... |
Publication Detail:
|
Type: Journal Article Date: 2010-04-08 |
Journal Detail:
|
Title: Journal of cardiology Volume: 56 ISSN: 0914-5087 ISO Abbreviation: J Cardiol Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-07-08 Completed Date: 2010-09-30 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8804703 Medline TA: J Cardiol Country: Japan |
Other Details:
|
Languages: eng Pagination: 66-72 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved. |
Affiliation:
|
Department of Cardiology, Hyogo Prefectural Amagasaki Hospital, Higashidaimotsucho 1-1-1, Amagasaki, Hyogo 660-0828, Japan. cardioys@kuhp.kyoto-u.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Atrial Natriuretic Factor / blood, therapeutic use* Blood Pressure Female Heart Failure / blood*, drug therapy, physiopathology Humans Male Nitrates / therapeutic use* Troponin I / blood* Vasodilator Agents / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/NPPA protein, human; 0/Nitrates; 0/Troponin I; 0/Vasodilator Agents; 85637-73-6/Atrial Natriuretic Factor |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Relation between prognosis and myocardial perfusion imaging from the difference of end-point criteri...
Next Document: The psychosis risk syndrome and its proposed inclusion in the DSM-V: a risk-benefit analysis.